98%
921
2 minutes
20
The H3K4 methyltransferase SETD1A plays a crucial role in leukemia cell survival through its noncatalytic FLOS domain-mediated recruitment of cyclin K and regulation of DNA damage response genes. In this study, we identify a functional nuclear localization signal in and interaction partners of the FLOS domain. Our screen for FLOS domain-binding partners reveals that the SETD1A FLOS domain binds mitosis-associated proteins BuGZ/BUB3. Inhibition of both cyclin K and BuGZ/BUB3-binding motifs in SETD1A shows synergistic antileukemic effects. BuGZ/BUB3 localize to SETD1A-bound promoter-TSS regions and SETD1A-negative H3K4me1-positive enhancer regions adjacent to SETD1A target genes. The GLEBS motif and intrinsically disordered region of BuGZ are required for both SETD1A-binding and leukemia cell proliferation. Cell-cycle-specific SETD1A restoration assays indicate that SETD1A expression at the G1/S phase of the cell cycle promotes both the expression of DNA damage response genes and cell cycle progression in leukemia cells.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561176 | PMC |
http://dx.doi.org/10.15252/embr.202357108 | DOI Listing |
Turk J Pediatr
September 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.
Background: Glucocorticoids remain the primary treatment for acute lymphoblastic leukemia (ALL) in children. However, glucocorticoid-resistant ALL exhibits increased mortality rates. To overcome resistance and improve management strategies, alternative therapeutic agents are required.
View Article and Find Full Text PDFOcular relapse in pediatric acute lymphoblastic leukemia (ALL) is rare and typically associated with central nervous system or bone marrow involvement. Anterior segment infiltration as the sole manifestation of relapse is exceptionally uncommon and may mimic noninfectious uveitis, leading to diagnostic delay. We report the case of a 4-year-old boy with a history of B-cell precursor ALL, diagnosed at age 2 and treated according to the ALL IC BFM 2009 protocol.
View Article and Find Full Text PDFBlood Adv
September 2025
AP-HP, Hôpital Saint Louis and University of Paris, INSERM U944 and THEMA insitute, Paris, France.
Germline DDX41 mutations (DDX41mut) are identified in approximately 5% of myeloid malignancies with excess of blasts, representing a distinct MDS/AML entity. The disease is associated with better outcomes compared to DDX41 wild-type (DDX41WT), but patients who do not undergo allogeneic hematopoietic stem cell transplantation (HSCT) may experience late relapse. Due to the recent identification of DDX41mut, data on post-HSCT outcomes remain limited.
View Article and Find Full Text PDFAnal Chem
September 2025
School of Chemistry and Chemical Engineering, Shandong University of Technology, Zibo 255049, PR China.
Pax-5a gene, as a nucleic acid biomarker closely associated with B-cell acute lymphoblastic leukemia (B-ALL), holds significant potential for early disease diagnosis. In this study, we developed a highly accurate and efficient "on-super on-off" photoelectrochemical (PEC) biosensor based on a dual-photoelectrode heterojunction system integrated with a multisphere cascade DNA amplification strategy. The designed heterojunction dual-photoelectrode platform, comprising a InO/CdS photoanode (on state) and an in situ-formed MIL-68(In)/InO (MIO) photocathode, effectively extends the electron-hole transport pathway, enhances photogenerated charge separation, and produces high-amplitude signal output (super on state), thereby providing a robust baseline for signal transduction.
View Article and Find Full Text PDFArch Pharm Res
September 2025
Department of Biosciences, JIS University, 81, Nilgunj Road, Agarpara, Kolkata, West Bengal, 700109, India.
Bacoside A (BCA), a triterpenoid saponin isolated from Bacopa monnieri, exhibits diverse pharmacological properties, including neuroprotective, hepatoprotective, anti-stress, anti-inflammatory, and anti-ulcer effects. In the present study, BCA demonstrates pronounced anticancer activity against K562 chronic myelogenous leukemia (CML) cells by modulating autophagy-apoptosis dynamics. BCA induces dose- and time-dependent cytotoxicity in K562 cells while sparing normal human peripheral blood mononuclear cells (hPBMCs) and Vero cells, indicating therapeutic selectivity.
View Article and Find Full Text PDF